Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China

Abstract This is the first report of ceftazidime–avibactam resistance caused by the blaKPC-33 mutation through the D179Y variant during the treatment of blaKPC-2-positive Klebsiella pneumoniae-related infections in China. The blaKPC-33-containing K. pneumoniae was susceptible to meropenem–vaborbacta...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 71; no. Supplement_4; pp. S436 - S439
Main Authors Shi, Qingyu, Yin, Dandan, Han, Renru, Guo, Yan, Zheng, Yonggui, Wu, Shi, Yang, Yang, Li, Shirong, Zhang, Rong, Hu, Fupin
Format Journal Article
LanguageEnglish
Published US Oxford University Press 23.12.2020
Subjects
Anti-Bacterial Agents - pharmacology
Azabicyclo Compounds - pharmacology
Bacterial Proteins - genetics
beta-Lactamases - genetics
Ceftazidime
China
Drug Combinations
Humans
Klebsiella Infections - epidemiology
Klebsiella pneumoniae - genetics
Microbial Sensitivity Tests
China
Ceftazidime-avibactam
Carbapenem-resistant
Meropenem-vaborbactam
bla KPC-2
Carbapenem-resistant K. pneumoniae
bla KPC-33
Online AccessGet full text

Cover

More Information
Summary:Abstract This is the first report of ceftazidime–avibactam resistance caused by the blaKPC-33 mutation through the D179Y variant during the treatment of blaKPC-2-positive Klebsiella pneumoniae-related infections in China. The blaKPC-33-containing K. pneumoniae was susceptible to meropenem–vaborbactam, cefepime–zidebactam, tigecycline, and polymyxin B. The blaKPC-33 gene was located on a 77 551-bp transformable plasmid harboring qnrS1 and blaLAP-2. Detecting blaKPC-33-positive K. pneumoniae clinical strains is important for infection control.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa1521